David Sly, DO
Family Medicine · San Francisco, CANPI 1255387148
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Amgen at 43.1% of the total.
Across 28 payments — averaging $13.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$162
- Boehringer Ingelheim$79
- Novo Nordisk$55
- Astellas Pharma US Inc$28
- Shire North American Group Inc$16
- Genentech USA, Inc.$14
- plus $22 from 2 others
What the payments were for
- Food & beverage$376100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 12 | $162 |
| Boehringer Ingelheim | 6 | $79 |
| Novo Nordisk | 4 | $55 |
| Astellas Pharma US Inc | 2 | $28 |
| Shire North American Group Inc | 1 | $16 |
| Genentech USA, Inc. | 1 | $14 |
| Pfizer | 1 | $11 |
| Merck | 1 | $11 |
How this compares
$376 in reported general payments places this provider in the 55th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 16 | $518 |
| Valsartan | 12 | $480 |
| Tamsulosin Hcl | 27 | $470 |
| Levothyroxine Sodium | 45 | $415 |
| Atorvastatin Calcium | 49 | $408 |
| Bupropion XlBupropion Hcl | 11 | $399 |
| Rosuvastatin Calcium | 32 | $380 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $308 |
| Escitalopram Oxalate | 11 | $298 |
| Lisinopril | 31 | $175 |
| Amlodipine Besylate | 26 | $173 |
| Metformin Hcl ErMetformin Hcl | 11 | $167 |
| Metoprolol Succinate | 11 | $144 |
| Doxycycline Monohydrate | 14 | $127 |
| Losartan Potassium | 13 | $118 |
Paid to pharmacies, not to this prescriber.
Other family medicine in San Francisco
- Nasser MohamedSan Francisco$278K
- Colleen RileySan Francisco$115K
- Konstantin BukovSan Francisco$75K
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.